首頁(yè) > 抗體/蛋白 > 藥物對(duì)照抗體

瀏覽量: 170

產(chǎn)品名稱(chēng)： Research Grade Mepolizumab ( 美泊珠單抗 )
產(chǎn)品貨號(hào)： CSD00030
貨期： 現(xiàn)貨
價(jià)格與訂購(gòu)： 2480
數(shù)量：

庫(kù)存： 100
規(guī)格： 100μg

產(chǎn)品信息
如何訂購(gòu)

貨號(hào)（Catalog No.）

CSD00030

通用名INN

Mepolizumab

純度(Purity)

>95%

濃度( Concentration)

1mg/ml

Formulation

PBS buffer PH7.5

Source

CHO cells

內(nèi)毒素(Endotoxin level)

Please contact with the lab for this information.

產(chǎn)品描述(Description)

Mepolizumab is a humanized IL-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells.It has a molecular weight of approximately 149 kDa.It was approved by the FDA in November,2015 for the treatment of asthma under the brand name Nucala (marketed by GlaxoSmithKline).Mepolizumab has been investigated in the treatment of severe nasal polyposis,among numerous other conditions.Mepolizumab is an interleukin-5 antagonist (IgG1 kappa).IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation,and survival of eosinophils.Mepolizumab binds to IL-5 with a dissociation constant of 100 pM,inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface.Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells,eosinophils, neutrophils,macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation.Mepolizumab,by inhibiting IL-5 signaling, reduces the production and survival of eosinophils;however,the mechanism of mepolizumab action in asthma has not been definitively established.

別名(Alternative names)

SB-240563

靶點(diǎn);物種(Specificity target name;species)

IL5[Homo sapiens]

種類(lèi)(Species)

Humanized

受體鑒定(Receptor identification)

IgG1-kappa

分子量(MV)

149000.00 Da

CAS

196078-29-2